Tag: bisphosphonate

News

09/28/11

Zoledronic acid might reduce recurrence in postmenopausal women

12/10/10

Adding zoledronic acid to chemotherapy does not improve markers

Studies

• Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines Cite
  Bodgi L, Bou-Gharios J, Azzi J, Challita R, Feghaly C, Baalbaki K, et al. Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines. Pharmacological Reports. Springer Science and Business Media LLC; 2023; 10.1007/s43440-023-00560-7
• Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation Cite
  Hahm E, Kim S, Pore SK, Mathan SV, Singh RP, Singh SV. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation. Molecular Carcinogenesis. Wiley; 2023; 10.1002/mc.23653
• Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole. Cite
  Abdel Gelil M. Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2023; 9:8-8 10.1200/go.2023.9.supplement_1.8
• The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials Cite
  Liu M, Qian S, Wu J, Xiao J, Zeng X. The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials. Asian Journal of Surgery. Elsevier BV; 2023; 10.1016/j.asjsur.2023.01.049
• Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment Cite
  Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, et al. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment. JAMA Oncology. American Medical Association (AMA); 2021; 10.1001/jamaoncol.2021.1854
• Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells Cite
  Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. Elsevier BV; 2020; 10.1016/j.jtumed.2020.10.017
• Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis Cite
  Peng R, Liang X, Zhang G, Yao Y, Chen Z, Pan X, et al. Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis. BioMed Research International. Hindawi Limited; 2020; 2020:1-13 10.1155/2020/5606573
• Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307 Cite
  Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, et al. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2019; 112:698-707 10.1093/jnci/djz215
• Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? Cite
  Brufsky A, Mathew A. Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2019; 112:659-660 10.1093/jnci/djz216
• Survival in older women with early stage breast cancer receiving low‐dose bisphosphonates or denosumab Cite
  Suarez‐Almazor ME, Herrera R, Lei X, Chavez‐MacGregor M, Zhao H, Giordano SH. Survival in older women with early stage breast cancer receiving low‐dose bisphosphonates or denosumab. Cancer. Wiley; 2020; 126:3929-3938 10.1002/cncr.33035
• Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial Cite
  van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, et al. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:675-685 10.1007/s10549-020-05567-9
• Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population. Cite
  Johnson A, Agbisit C, Robinson K, Delfino K, Desai MR. Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e12048-e12048 10.1200/jco.2019.37.15_suppl.e12048
• The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women Cite
  Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N, et al. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. Journal of Bone Oncology. Elsevier BV; 2019; 16:100202 10.1016/j.jbo.2018.10.001
• Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation Cite
  Tanaka M, Itoh S, Takeuchi Y. Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation. Osteoporosis and Sarcopenia. Elsevier BV; 2018; 4:102-108 10.1016/j.afos.2018.08.002
• Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors Cite
  Bouvard B, Chatelais J, Soulié P, Hoppé E, Saulnier P, Capitain O, et al. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. European Journal of Cancer. Elsevier BV; 2018; 101:87-94 10.1016/j.ejca.2018.06.028
• PO-004 The clinical relevance and functional role of ACADM in hepatocellular carcinoma Cite
  APY M, Mao X, Tey S, FCF K, Yam J. PO-004 The clinical relevance and functional role of ACADM in hepatocellular carcinoma. Sunday Poster Presentation. BMJ Publishing Group Ltd; 2018; 10.1136/esmoopen-2018-eacr25.49
• Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial Cite
  Kyvernitakis I, Kann PH, Thomasius F, Hars O, Hadji P. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone. Elsevier BV; 2018; 114:109-115 10.1016/j.bone.2018.06.007
• Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients Cite
  Korde LA, Doody DR, Hsu L, Porter PL, Malone KE. Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 27:165-173 10.1158/1055-9965.epi-17-0556
• Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro Cite
  Gschwantler-Kaulich D, Weingartshofer S, Grunt TW, Mairhofer M, Tan Y, Gamper J, et al. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0185566 10.1371/journal.pone.0185566
• Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines Cite
  Karlic H, Haider F, Thaler R, Spitzer S, Klaushofer K, Varga F. Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines. International Journal of Molecular Sciences. MDPI AG; 2017; 18:1982 10.3390/ijms18091982
• Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies Cite
  Ou Y, Chiu H, Wong Y, Yang C, Yang Y. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety. Wiley; 2017; 26:1286-1295 10.1002/pds.4302
• Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer Cite
  Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, et al. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer. Journal of Surgical Research. Elsevier BV; 2017; 220:46-51 10.1016/j.jss.2017.05.066
• Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women Cite
  Fournier A, Mesrine S, Gelot A, Fagherazzi G, Baglietto L, Clavel-Chapelon F, et al. Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3230-3239 10.1200/jco.2016.71.4337
• Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline Cite
  Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:2062-2081 10.1200/jco.2016.70.7257
• Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG Cite
  Hadji P, Aapro MS, Body J, Gnant M, Brandi ML, Reginster JY, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology. Elsevier BV; 2017; 7:1-12 10.1016/j.jbo.2017.03.001
• Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells Cite
  Ubellacker JM, Haider M, DeCristo MJ, Allocca G, Brown NJ, Silver DP, et al. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0815-8
• Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience Cite
  Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience. International Journal of Dentistry. Hindawi Limited; 2016; 2016:1-9 10.1155/2016/1801676
• Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy Cite
  Kasimir-Bauer S, Bittner A, König L, Reiter K, Keller T, Kimmig R, et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0679-3
• Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration Cite
  Mammo Z, Guo M, Maberley D, Matsubara J, Etminan M. Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration. American Journal of Ophthalmology. Elsevier BV; 2016; 168:62-67 10.1016/j.ajo.2016.04.022
• Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) Cite
  von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, et al. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer. Elsevier BV; 2016; 64:12-21 10.1016/j.ejca.2016.05.015
• Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial Cite
  Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen G, et al. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. Bone. Elsevier BV; 2016; 90:123-126 10.1016/j.bone.2016.03.010
• Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen Cite
  Kwan ML, Shi JM, Habel LA, Song J, Chung JW, Avila CC, et al. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:379-389 10.1007/s10549-016-3763-6
• Abstract P6-13-19: Adding zoledronic acid to neo-adjuvant chemotherapy may improve the efficiency of chemotherapy in locally advanced breast cancer: Results from the prospective randomized study NEOZOL Cite
  Mathevet P, Magaud L, Clézardin P. Abstract P6-13-19: Adding zoledronic acid to neo-adjuvant chemotherapy may improve the efficiency of chemotherapy in locally advanced breast cancer: Results from the prospective randomized study NEOZOL. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p6-13-19
• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel Cite
  Hadji P, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology. Elsevier BV; 2016; 27:379-390 10.1093/annonc/mdv617
• Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Cite
  Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The Lancet. Elsevier BV; 2015; 386:1353-1361 10.1016/s0140-6736(15)60908-4
• Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis Cite
  Su G, Xiang Y, He G, Jiang C, Li C, Yan Z, et al. Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis. Archives of Medical Research. Elsevier BV; 2014; 45:570-579 10.1016/j.arcmed.2014.10.007
• Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines Cite
  IBRAHIM T, LIVERANI C, MERCATALI L, SACANNA E, ZANONI M, FABBRI F, et al. Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines. International Journal of Oncology. Spandidos Publications; 2013; 42:1263-1270 10.3892/ijo.2013.1809
• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Cite
  Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology. Elsevier BV; 2013; 24:398-405 10.1093/annonc/mds277
• Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid Cite
  Dedes P, Gialeli C, Tsonis A, Kanakis I, Theocharis A, Kletsas D, et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochimica et Biophysica Acta (BBA) - General Subjects. Elsevier BV; 2012; 1820:1926-1939 10.1016/j.bbagen.2012.07.013
• Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer Cite
  Monsees GM, Malone KE, Tang MC, Newcomb PA, Li CI. Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1752-1760 10.1093/jnci/djr399
• Final 5-year results of Z-FAST trial Cite
  Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial. Cancer. Wiley; 2011; 118:1192-1201 10.1002/cncr.26313
• Breast-Cancer Adjuvant Therapy with Zoledronic Acid Cite
  Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1396-1405 10.1056/nejmoa1105195
• Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. Cite
  Pfeiler G, Königsberg R, Mlineritsch B, Stoger H, Singer CF, Poestlberger S, et al. Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:514-514 10.1200/jco.2011.29.15_suppl.514
• Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer Cite
  Winter M, Syddall S, Cross S, Evans A, Ingram C, Jolley I, et al. Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts. American Association for Cancer Research; 2010; 10.1158/0008-5472.sabcs10-p1-11-01
• Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials Cite
  Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, et al. Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2010; 8:279-286 10.6004/jnccn.2010.0020
• Outcome of Patients With Early Breast Cancer Receiving Nitrogen-Containing Bisphosphonates: A Comparative Analysis From the Metropolitan Detroit Cancer Surveillance System Cite
  Nahleh Z, Abrams J, Bhargaval A, Nirmal K, Graff JJ. Outcome of Patients With Early Breast Cancer Receiving Nitrogen-Containing Bisphosphonates: A Comparative Analysis From the Metropolitan Detroit Cancer Surveillance System. Clinical Breast Cancer. Elsevier BV; 2010; 10:459-464 10.3816/cbc.2010.n.060
• Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? Cite
  Coleman R. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy?. European Journal of Cancer. Elsevier BV; 2009; 45:1909-1915 10.1016/j.ejca.2009.04.022